Ponezumab

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Ponezumab
Monoclonal antibody
Type Whole antibody
Source Humanized (from mouse)
Target beta-amyloid
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
Formula C6552H10158N1730O2090S52
Molar mass 148.3 kg/mol
 NYesY (what is this?)  (verify)

Ponezumab is a humanized monoclonal antibody designed for the treatment of Alzheimer's disease.[1]

Ponezumab was developed by Pfizer Inc. In November 2011 Pfizer halted the development of ponezumab after finishing a phase 2 trial.[2] Detailed reports have to be released.

References[edit]

  1. ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Ponezumab" (PDF). American Medical Association. 
  2. ^ "Alzforum".